CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH At 12 months, nivolumab plus chemotherapy yielded a PFS of 89.3% versus 60.7% for
chemotherapy alone and an OS of 98.2% compared with 82.1%, respectively. The
combination improved median PFS by 52% compared with chemotherapy alone at a
median follow-up of 26.1 months. (See also NADIM II and IMpower010 Provide Support for Neoadjuvant and Adjuvant Immunotherapy in Lung Cancer)
Peer-influenced content. Sources you trust. No registration required. This is HCN.
